OBJECTIVE: To probe into the efficacy of Kelu oral liquid combined with ketotifen in the treatment of cough variant asthma and its effects on immune function and inflammatory factors. METHODS: Totally 150 patients with cough variant asthma admitted into Zhangjiagang Traditional Chinese Medicine Hospital from Mar. 2016 to Oct. 2018 were extracted to be divided into the control group and the study group via the random number table

with 75 cases in each group. The control group was given ketotifen

while the study group additionally received Kelu oral liquid bases on the control group. The clinical efficacy

immune function

inflammatory factors [interleukin 4（ IL-4）

γ-interferon（ IFN-γ） ]levels

life quality

and incidence of adverse drug reactions of two groups were compared. RESULTS: After treatment of 2 months

the total effective rate of the study group was 72. 00%（ 54/75）

significantly higher than56. 00%（ 42/75） in the control group

the difference was statistically significant（ P < 0. 05）. After treatment of 2 months

the levels of CD4+

CD4+/CD8+in two groups were significantly higher than those before treatment

and the study group was significantly higher than that of the control group; the levels of CD8+were significantly lower than those before treatment

and the study group was significantly lower than the control group

the above differences were statistically significant（ P < 0. 05）. After treatment of 2 months

the levels of IL-4 in two groups were significantly lower than those before treatment

and the study group was significantly lower than the control group; the levels of IFN-γ in two groups were significantly higher than those before treatment

and the study group was significantly higher than the control group

with statistically significant differences（ P < 0. 05）. After treatment of 2 months

the activity of daily living scores in two groups were significantly higher than those before treatment

and the study group was significantly higher than the control group

with statistically significant differences（ P < 0. 05）. The incidence of adverse drug reactions in the control group and the study group were 16. 00%（ 12/75） and 18. 67%（ 14/75）

with no significant difference（ P = 0. 666）. CONCLUSIONS: The efficacy of Kelu oral liquid combined with ketotifen in the treatment of cough variant asthma is significant

can effectively improve the immune function and the levels of inflammatory factors without increasing the incidence of adverse drug reactions

and has higher clinical values.